Literature DB >> 25299787

Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T.

Jung Jae Park1, Chan Kyo Kim, Sung Yoon Park, Byung Kwan Park.   

Abstract

PURPOSE: To retrospectively investigate the value of fused T2-weighted and high-b-value diffusion-weighted imaging with background body signal suppression (DWIBS) at 3 T to evaluate parametrial invasion in cervical cancer.
MATERIALS AND METHODS: In this institutional review board-approved study, 152 consecutive patients with biopsy-proven cervical cancer who underwent radical hysterectomies also underwent pretreatment magnetic resonance imaging (T2-weighted imaging and DWIBS) at 3 T. Two radiologists independently evaluated the presence of parametrial invasion at T2-weighted imaging, fused T2-weighted imaging and high-b-value DWIBS (ie, fused T2-weighted DWIBS), and combined T2-weighted imaging and fused T2-weighted DWIBS, and the results were compared with histopathologic findings.
RESULTS: Parametrial invasion was identified by pathologic analysis in 37 of 152 patients (24.3%). For association with parametrial invasion, the specificity and accuracy of fused T2-weighted DWIBS (97.4% and 90.1%, respectively, for reader 1; 95.7% and 89.5%, respectively, for reader 2) and combined T2-weighted imaging and fused T2-weighted DWIBS (99.1% and 93.4%, respectively, for reader 1; 96.5% and 92.8%, respectively, for reader 2) were significantly better than those of T2-weighted imaging alone (88.7% and 85.5%, respectively, for reader 1; 85.2% and 83.6%, respectively, for reader 2) (all P < .05). The respective sensitivity of T2-weighted imaging, fused T2-weighted DWIBS, and combined T2-weighted imaging and fused T2-weighted DWIBS was 75.7%, 67.6%, and 75.7% for reader 1 and 78.4%, 70.3%, and 81.1% for reader 2, and did not show significant differences (P value, ≤.375 to >.999). The respective area under the curve for association with parametrial invasion of T2-weighted imaging, fused T2-weighted DWIBS, and combined T2-weighted imaging and fused T2-weighted DWIBS was 0.912, 0.951, and 0.976 for reader 1 and 0.890, 0.932, and 0.968 for reader 2 (P < .05). Interreader agreements were excellent (κ = 0.89, 0.9, and 0.86 for T2-weighted imaging, fused T2-weighted DWIBS, and combined T2-weighted imaging and fused T2-weighted DWIBS, respectively).
CONCLUSION: Fusion of high-b-value DWIBS with T2-weighted imaging can improve the diagnostic performance in association with parametrial invasion in cervical cancer compared with T2-weighted imaging alone.

Entities:  

Mesh:

Year:  2014        PMID: 25299787     DOI: 10.1148/radiol.14140920

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

2.  Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion.

Authors:  Minsu Lee; Su-Jin Shin; Young Taik Oh; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Sung Yoon Park
Journal:  Eur Radiol       Date:  2017-02-06       Impact factor: 5.315

Review 3.  Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: An updated systematic review and meta-analysis of the literature between 2012 and 2016.

Authors:  Sungmin Woo; Chong Hyun Suh; Sang Youn Kim; Jeong Yeon Cho; Seung Hyup Kim
Journal:  Eur Radiol       Date:  2017-07-19       Impact factor: 5.315

4.  Reduced field-of-view diffusion-weighted MRI in patients with cervical cancer.

Authors:  Jiyoung Hwang; Seong Sook Hong; Hyun-Joo Kim; Yun-Woo Chang; Bo Da Nam; Eunsun Oh; EunJi Lee; Hwajin Cha
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 5.  Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.

Authors:  Shinya Matsuzaki; Maximilian Klar; Mikio Mikami; Muneaki Shimada; Brendan H Grubbs; Keiichi Fujiwara; Lynda D Roman; Koji Matsuo
Journal:  Curr Oncol Rep       Date:  2020-02-12       Impact factor: 5.075

6.  Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.

Authors:  Jung Jae Park; Chan Kyo Kim; Byung Kwan Park
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

7.  Independent value of image fusion in unenhanced breast MRI using diffusion-weighted and morphological T2-weighted images for lesion characterization in patients with recently detected BI-RADS 4/5 x-ray mammography findings.

Authors:  Sebastian Bickelhaupt; Jana Tesdorff; Frederik Bernd Laun; Tristan Anselm Kuder; Wolfgang Lederer; Susanne Teiner; Klaus Maier-Hein; Heidi Daniel; Anne Stieber; Stefan Delorme; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2016-05-18       Impact factor: 5.315

8.  Features and perspectives of MR enterography for pediatric Crohn disease assessment.

Authors:  Noemi Maria Giovanna Ognibene; Massimo Basile; Marco Di Maurizio; Giuseppe Petrillo; Claudio De Filippi
Journal:  Radiol Med       Date:  2016-02-02       Impact factor: 3.469

Review 9.  Implications of the new FIGO staging and the role of imaging in cervical cancer.

Authors:  Aki Kido; Yuji Nakamoto
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

Review 10.  Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT.

Authors:  Madeleine Sertic; Aoife Kilcoyne; Onofrio Antonio Catalano; Susanna I Lee
Journal:  Abdom Radiol (NY)       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.